Ten percent tapering rule
The ten percent rule is a rule of thumb for coming off an antidepressant with fewer withdrawal symptoms: each step takes off about 10% of the current dose, and you hold there, in the original rule for about a month, before the next step. The cuts get smaller as the dose falls. The figure comes from patient support communities, not from trials or official guidance. Guidance agrees with cuts that get smaller as the dose falls, but the size and pace of each step are best agreed with your prescriber and adjusted to how you feel.
Also called: 10% taper, Ten percent rule, 10% rule.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
This page covers the ten percent rule as people use it when tapering an antidepressant. Other fields use the same phrase for other things.
What is the ten percent rule?
Take about 10% off the dose you are on now, hold it, then take 10% off the new dose. Ten percent of 20 mg is 2 mg; ten percent of 5 mg is 0.5 mg. The steps keep shrinking as the dose falls, and that is the point of the rule. How long to hold each step is not part of the figure, and that part is set with your prescriber.
It is a plain version of proportional, or hyperbolic, tapering. In a 2019 paper in The Lancet Psychiatry, Horowitz and Taylor argued that SSRIs should be tapered hyperbolically and slowly, to doses much lower than the usual therapeutic minimum. Their reason comes from serotonin transporter occupancy: cutting the dose by a share each time makes the effect on the serotonin transporter fall in a linear way, while tapers of 2 to 4 weeks down to the minimum dose show minimal benefit over stopping at once.
Is a ten percent taper safe to do on your own?
The rule describes the size of a step, not permission to set your own doses. The small doses at the end usually need a liquid or a dissolving tablet, and a prescriber and pharmacist arrange that. A 2026 paper by Horowitz and Perry in the African Journal of Primary Health Care and Family Medicine says abrupt discontinuation should be avoided, that people at higher risk may need very gradual tapering over months or years with hyperbolic reductions enabled by liquid formulations or dissolving tablets, and that patients should be seen every 2 to 4 weeks after a reduction so a taper can be paused or reversed if symptoms appear.
Symptoms on the way down are common. That 2026 paper puts withdrawal at at least half of the people who stop, with risk and severity rising with higher doses and longer treatment, while other analyses put the share lower; the estimates differ mostly in how symptoms were counted. A 2026 review in Australian Prescriber adds that withdrawal symptoms are more likely with longer treatment and with certain medications, naming duloxetine, venlafaxine and paroxetine. If you feel much worse after a step, tell your prescriber that week rather than at your next appointment.
Is a ten percent step fast or slow?
Slower than most guidelines, faster than some patient tapers. US labels give no schedule: the Zoloft label says adverse reactions may occur on discontinuation and to reduce the dosage gradually rather than stopping abruptly whenever possible, and leaves the size of the steps to the prescriber. The 2026 review in Australian Prescriber says the optimal tapering approach is not yet known, that tapering usually means smaller decrements as the dose is lowered, and that for people at low risk of withdrawal symptoms guidelines recommend 25% to 50% dose reductions over 2 to 6 weeks, while people at higher risk may need smaller reductions over many weeks or months, through to very low doses such as sertraline 1 mg.
Pace itself has been measured. In a 2023 study of 608 people tapering with tapering strips, mostly after earlier attempts to stop had failed, daily steps averaging 4.5% of the previous dose came with less withdrawal than weekly steps averaging 33.4%. Most of them were coming off venlafaxine or paroxetine. Withdrawal stayed limited overall and tracked how fast the taper went. The two rates were compared inside one method, and nobody was assigned to a group, so the study does not say how a 10% step compares with other ways of coming down.
Why does ten percent not suit everyone?
Because the number is convenient rather than measured. In the 2023 study, women, younger people and those with risk factors reported more withdrawal, as did people on faster schedules, so the same step can land differently on two people taking the same drug.
That is why the rule is written with room to move: a step can be held longer, or the next one made smaller, when the last one was rough. Which step and how long to hold it is a decision with your prescriber, made on what the last step did.
What to do
Take the number to your prescriber as a starting question: ask whether steps of about 10% of the current dose suit your medication, how long to hold each step, and which form gets you the small doses near the end. Write down the date of each reduction, the dose you moved to, and how the days after it went, so the next step is decided on what happened rather than on the calendar. If symptoms are hard to bear, tell your prescriber that week. If you have thoughts of harming yourself, call or text 988 in the US, or your local emergency number.
See what proportional steps look like for your dose
How withClaro helps
- Each reduction dated, with the dose you moved to
- How you felt in the days after a drop
- A PDF report of the taper for your prescriber
Get the withClaro app on the App Store
Related terms
Sources
- Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 2019.
- van Os J, Groot PC. Outcomes of hyperbolic tapering of antidepressants. Therapeutic Advances in Psychopharmacology, 2023.
- Wallis KA. Stopping antidepressants: when and how. Australian Prescriber, 2026.
- Horowitz M, Perry TL. Stopping antidepressants safely. African Journal of Primary Health Care & Family Medicine, 2026.
- U.S. Food and Drug Administration. Zoloft (sertraline) tablets and oral solution: prescribing information. FDA / DailyMed, 2025.
All glossary terms